Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 21, 2026
TickeronGET DAILY SIGNALS
GE HealthCare (GEHC) Rises +12.9% on Strong Earnings and Raised Guidance

GE HealthCare (GEHC) Rises +12.9% on Strong Earnings and Raised Guidance

Key Takeaways

  • GE HealthCare (GEHC) shares advanced about 12.9% over the last 30 days, climbing from a closing price of $71.42 on October 22 to $80.64 on November 20.
  • The move was fueled largely by a stronger-than-expected Q3 2026 earnings report, with adjusted EPS of $1.34 beating the roughly $1.21 consensus and revenue rising 7.2% year over year.
  • Management raised its full-year 2026 guidance and increased its quarterly dividend by 14%, reinforcing investor confidence in the turnaround.
  • Growth was broad-based: Pharmaceutical Diagnostics rose 13.8% organically, while Patient Care Solutions returned to 8.8% organic growth.
  • Offsetting factors include a slowdown in organic order growth to 4% and ongoing tariff, inflation, and China-related uncertainties.
  • For deeper detail on the company's outlook, review its Price Targets, Earnings, and Forecast pages.

Company Background and Market Position

GE HealthCare Technologies Inc. is a Chicago-based medical technology company that was spun off from General Electric in early 2023. It develops, manufactures, and services imaging equipment—including CT, MRI, X-ray, and ultrasound systems—alongside patient monitoring solutions and pharmaceutical diagnostics such as contrast media and radiopharmaceuticals. Its reporting segments are Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics, serving hospitals, clinics, and health systems globally.

The company competes in large, regulated healthcare markets and is closely watched for its exposure to hospital capital-spending cycles, precision-medicine trends, and pricing pressure in China. Investors follow the stock for its diversified installed base, recurring service revenue, and growing position in high-growth areas such as radiopharmaceuticals and precision diagnostics. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent Stock Price Performance: Last 30 Days Versus the Quarter

Over the last 30 days, GEHC shares gained roughly 12.9%, rising from $71.42 on October 22 to $80.64 on November 20. The stock reached an intraday high of $87.56 on November 4 before consolidating into the low $80s.

The last quarter tells a more volatile story. Shares traded around the mid-$74 range in mid-August, then sold off through September to a closing low of $63.49 on September 16 as tariff and China-related concerns weighed on sentiment. The subsequent earnings-driven rebound lifted the stock to roughly $80.64 by November 20—an increase of about 7.8% from the August 21 close of $74.82, though the path was marked by a sharp September drawdown followed by a strong recovery.

What Fueled the Gains Over the Past Month

The primary catalyst was the company's third-quarter 2026 earnings report, released on October 28. Adjusted EPS of $1.34 rose 25.1% year over year and exceeded consensus estimates, while revenue of $5.51 billion increased 7.2%, with organic growth of 6.2%—an acceleration from 3.5% in the second quarter. Adjusted EBIT margin expanded 180 basis points to 16.6%, and free cash flow climbed to $793 million.

Management raised full-year 2026 guidance to approximately 4% organic revenue growth, adjusted EPS of $4.95–$5.05, and adjusted EBIT margin of 15.5%–15.7%, and increased the dividend by 14%. Strength in Pharmaceutical Diagnostics—up 13.8% organically—was a highlight, supported by contrast media and the Flyrcado radiopharmaceutical ramp to roughly 680 weekly doses. Patient Care Solutions also recovered, growing 8.8% organically after earlier operational challenges.

The report was not without caveats. Organic order growth slowed to 4% from 11.1% in the prior quarter, and book-to-bill slipped to 1.03x from 1.15x. A leadership transition in Patient Care Solutions and persistent tariff, memory-chip, and oil-cost inflation added caution, helping explain why the initial post-earnings surge later cooled from its November peak. From what I see, this earnings detail provides useful context for the move.

Quarterly Context and Recovery Narrative

The quarterly picture reflects a broader recovery narrative after a difficult first half of 2026. Earlier in the year, GEHC faced margin pressure from a pharmaceutical diagnostics supplier issue, tariff costs, and a decline in Patient Care Solutions, prompting a guidance reduction in the first quarter. Those challenges weighed on the stock into September, alongside sector-wide concerns about China volume-based procurement and tariff policy.

The third-quarter report marked an inflection point. Broad-based margin expansion, a record $23.7 billion backlog (up 12% year over year), and raised guidance reframed investor expectations. The planned $945 million acquisition of SOFIE Biosciences, announced in October, also signaled strategic investment in U.S. PET radiopharmaceutical supply and future tracer development. Even with the recent rally, however, the stock remained below its levels from earlier in 2026 on a year-to-date basis, reflecting lingering caution about order momentum and tariff exposure.

Key Factors to Monitor Going Forward

Investors will be watching several factors in the months ahead. Fourth-quarter results and formal 2027 guidance—expected in February—will provide the next major update on momentum, with management already flagging a difficult Patient Care Solutions comparison tied to a prior-year product-hold benefit. The planned closing of the SOFIE Biosciences acquisition in the first half of 2027 and the Flyrcado ramp toward a $500 million revenue run-rate target by 2028 are key strategic milestones.

Risks include unresolved Section 232 tariff policy, ongoing memory-chip and oil-cost inflation, China's expanding volume-based procurement program, and the potential for generic competition to Omnipaque. The trajectory of organic order growth and book-to-bill will be closely monitored as a leading indicator of future revenue. One thing that stands out here is how order trends could shape the next phase.

Using Tickeron AI Tools for Research

In my analysis of setups like this one, I often turn to Tickeron’s AI Trading Bots to review data-driven strategies across thousands of tickers. The platform allows users to evaluate different approaches based on performance metrics and timeframes, helping align ideas with individual goals and risk tolerance. It serves as a practical resource when assessing opportunities in volatile sectors.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GEHC

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


GEHC's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Indicator for GEHC moved out of overbought territory on November 11, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In 21 of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at 66%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GEHC as a result. In 44 of 71 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.

The Moving Average Convergence Divergence Histogram (MACD) for GEHC turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 20 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 53%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GEHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.

GEHC broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

GEHC moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for GEHC crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.

The 50-day moving average for GEHC moved above the 200-day moving average on November 11, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +7.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where GEHC advanced for three days, in 155 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.

The Aroon Indicator entered an Uptrend today. In 109 of 169 cases where GEHC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. GEHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.390) is normal, around the industry mean (4.142). P/E Ratio (18.938) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.666) is also within normal values, averaging (11.253). Dividend Yield (0.002) settles around the average of (0.011) among similar stocks. P/S Ratio (1.363) is also within normal values, averaging (40.124).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GEHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -36%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 49
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalNursingServices

Industry
N/A
Address
500 West Monroe Street
Phone
+1 833 735-1139
Employees
54000
Web
https://www.gehealthcare.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.